Scientists advising the British Government advised today to limit the use of AstraZeneca’s vaccine against coronavirus to people over 30 years of age when possible and to offer an alternative vaccine to those under 30, given evidence that links it to very rare cases of formation of blood clots
In a joint press conference with the advisers, the British regulator (MHRA) confirmed that the possibility of those immunized with the AstraZeneca vaccine developing thrombosis events is “extremely small” and that the benefits of its use outweigh its risks ” for the vast majority of people. “
British Prime Minister Boris Johnson said that the Government will follow the recommendation of the committee of experts, while his Minister of Health, Matt Hancock, welcomed that the regulatory body has concluded that the AstraZeneca vaccine, the most used in the United Kingdom , is safe and effective, and with more benefits than risks.
“The evidence is growing, and our review has concluded that, although there is a strong possibility, more work is needed to establish without a doubt that the vaccine caused these side effects,” said La MHRA Director June Raine.
The doctor reported that a review in late March in the United Kingdom found that of 20 million people inoculated with the AstraZeneca vaccine, 79 people suffered rare blood clots, 19 of whom died.
Sitting next to her, the chairman of the British Joint Committee for Vaccination and Immunization (JCVI), Wei Shen Lim, maintained that he was well aware of the benefit of coronavirus vaccines, but is also aware of the small risks.
For this reason, he recommended that an alternative to the drug developed by Oxford should be offered, if there is availability and if people between 18 and 29 years old are healthy, and are not at risk of becoming seriously ill from coronavirus.
“Adults between 18 and 29 years old who do not have comorbidities that put them at greater risk of suffering a severe form of Covid-19 should be offered an alternative vaccine to AstraZeneca, when such an alternative is available,” he said. , underlining that the committee does not recommend stopping vaccinating any age group.
Instead, for those who have received the first dose of the AstraZeneca vaccine, he said they should continue to be offered the second dose according to the established schedule.
The recommendation is in line with that made by other European countries, such as Germany, where it has been decided to restrict the AstraZeneca vaccine to some age groups after information emerged about rare events of blood clots in vaccinated.
Just today, another review by the European Medicines Agency (EMA) safety committee concluded that “unusual blood clots with low platelet levels should be included as very rare side effects” of the AstraZeneca vaccine.
The EMA scientists also insisted that the benefits of receiving the vaccine outweigh any possible risks despite fears about the effect of this drug in younger people, who have less risk of contracting coronavirus.
Meanwhile, the UK continues to administer the Pfizer-BioNTech vaccine and the American Moderna vaccine. that began to be applied today.
In total, more than 32 million people in the UK have already received at least one dose of the coronavirus vaccine and more than five million with the second dose. (Télam)